Abstract | OBJECTIVE: BACKGROUND: There are no established guidelines on treating patients with Guillain-Barré syndrome (GBS) who relapse or do not improve after a standard course of treatment ( IVIg or plasma exchange). Some centers will opt for a second course of the initial treatment. There is an ongoing trial of a second course of IVIg in patients with severe GBS. METHODS: We retrospectively reviewed 4 patients with severe GBS who received high-dose IVIg. One patient inadvertently received a high dose of IVIg for Miller Fisher syndrome. All patients received a total of at least 2 courses of the standard dose of IVIg (total >4 g/kg). We review their clinical course and side effects. RESULTS: CONCLUSION:
Hemolytic anemia may limit doses of IVIg for treatment of severe GBS in patients with non-O blood types.
|
Authors | Thy P Nguyen, Suur Biliciler, Amer Wahed, Kazim Sheikh |
Journal | Neurology(R) neuroimmunology & neuroinflammation
(Neurol Neuroimmunol Neuroinflamm)
Vol. 1
Issue 4
Pg. e50
(Dec 2014)
ISSN: 2332-7812 [Print] United States |
PMID | 25520957
(Publication Type: Journal Article)
|